29 Oral Cancer and Wound Healing

Thursday, March 22, 2012: 8 a.m.-9:30 a.m.
Session Type: Oral Session
1.5 CE hours

Learning Objectives:
To understand the mechanisms by which bisphosphonates modulate the inflammatory process via their effects on SOCS3 and inflammatory cytokine production
To evaluate oral cancer chemoprevention trials.
To evaluate post-prophylaxis plaque accumulation with a 0.1% cetylpryidinium chloride mouthrinse
Evaluation of a Mucoadhesive Fenretinide Patch for Oral Cancer Chemoprevention
A.S. HOLPUCH1, M.P. PHELPS1, K. DESAI2, W. CHEN3, G.M. KOUTRAS1, M. BORDER1, B. HAN1, M. TONG1, P. PEI1, B. WARNER4, H. FIELDS5, P.E. LARSEN1, G.D. STONER6, Z. LIU3, S.P. SCHWENDEMAN2, and S.R. MALLERY1, 1Oral and Maxillofacial Surgery, Pathology, and Anesthesiology, Ohio State University, Columbus, OH, 2Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 3College of Pharmacy, Ohio State University, Columbus, OH, 4College of Dentistry, Ohio State University, Columbus, OH, 5Orthodontics, Ohio State University, Columbus, OH, 6Medical College of Wisconsin, Milwuakee, WI
Endosomolytic Peptide-Mediated Delivery of Therapeutic siRNAs into Oral Cancer Cells
M. SOKOLOSKY, and A. JAKYMIW, Dept. of Craniofacial Biology, Medical University of South Carolina, Charleston, SC
Zoledronic Acid enhances proteasome-mediated degradation of SOCS3
W.T. VU1, C.P. JOHNSON1, P. ADESANYA1, L. RUEST1, and J. REUBEN2, 1Biomedical Sciences, Baylor College of Dentistry, Dallas, TX, 2Biomedical Sciences, University of Southern California, Greenville, SC
The indirect antinociceptive mechanism of 15d-PGJ2 on RA-induced TMJ hyperalgesia
J.T. CLEMENTE-NAPIMOGA, Piracicaba Dental School, State University of Campinas, Piracicaba, Brazil, M.D.S. QUINTEIRO, Department of Physiology, Piracicaba Dental School, State University of Campinas, Piracicaba, Brazil, and M.H. NAPIMOGA, Laboratory of Immunology and Molecular Biology, São Leopoldo Mandic Institute and Research Center, Piracicaba, Brazil
Cardiovascular Effects and Pharmacokinetics of Intranasal Tetracaine plus Oxymetazoline
E. HERSH1, L. LEVIN1, J. CHOU1, S. SECRETO1, T. CACEK2, M. HUTCHESON3, P. MOORE4, and H. GIANNAKOPOULOS1, 1School of Dental Medicine - Oral Surgery/Pharmacology, University of Pennsylvania, Philadelphia, PA, 2Pharmacokinetics, ContractKinetica, Columbia, MO, 3Biostatistics, Tegra Analytics LLC, Doylestown, PA, 4School of Dentistry, University of Pittsburgh, Pittsburgh, PA
2-Month Plaque Prevention Clinical Trial with 0.1% Cetylpryidinium Chloride Rinse
M.L. SINGH1, A. PAPAS2, S. SUNDARALINGAM2, E. TZAVARAS2, R. CHENG3, J. WITT3, and R. GERLACH3, 1Public Health and Community Service, Tufts University, Boston, MA, 2Oral Medicine, Tufts University, Boston, MA, 3Health Care Research Center, Procter & Gamble Company, Mason, OH